Naftopidil
As of the edition of 20 October 2026, Naftopidil is a small molecule: marketed, first approved in 1998 (JP); acts on ADRA1D.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1998
- Kind
- Small molecule
- First approved
- 25 December 1998 (JP)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Asahi Kasei Therapeutics
- Registered trials
- 4, 1 stopped early
- Disease areas
- Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Naftopidil.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRA1D | Alpha-1D adrenergic receptor | P25100 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Asahi Kasei Therapeutics | Originator | 1998 to now |